Helen Cho | Head of Global R&D
Samyang Holdings Corp. Biopharm Group

Helen Cho, PhD is the Head of global R&D of Samyang Biopharm Corporation and President of Samyang Biopharm USA Inc. In 2024 Samyang celebrates a century of business growth and expansion in the sectors of Chemical, Packaging, Food and Biopharmaceutical. R&D of Biopharmaceutical division is strategically focused on products for medical surgical care, medical aesthetics, anti-cancer pharmaceuticals and delivery systems for nucleic acid therapeutics, positioning the company as a key player of healthcare industry. Prior to Samyang, Helen served as the program director for immuno-oncology programs as a member of the Vaccine and Immunotherapeutics Department at Pfizer Inc. She led multidisciplinary R&D programs from discovery, genetic-antigen delivery platform development, to early clinical advancement for developing biological drugs for oncology. She received her Ph.D. in molecular biology and biochemistry from the University of Medicine and Dentistry of New Jersey and completed her postdoctoral training at the Salk Institute for Biological Studies.